Relyea Zuckerberg Hanson’s ARK Genomic Revolution ETF ARKG Stock Holding History

Relyea Zuckerberg Hanson’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,256	Closed	-$295K	–	237
2024 Q1	$295K	Sell	10,256 -1,405	-12%	-$42.3K	0.05%	184
2023 Q4	$383K	Buy	11,661 +1,220	+12%	+$33.2K	0.07%	139
2023 Q3	$291K	Buy	10,441 +762	+8%	+$24.9K	0.07%	150
2023 Q2	$330K	Sell	9,679 -1,808	-16%	-$56.8K	0.07%	138
2023 Q1	$345K	Hold	11,487	–	–	0.08%	125
2022 Q4	$324K	Buy	+11,487	New	+$365K	0.09%	126
2022 Q2	–	Sell	-6,619	Closed	-$292K	–	142
2022 Q1	$292K	Sell	6,619 -6,683	-50%	-$319K	0.1%	131
2021 Q4	$620K	Buy	13,302 +2,988	+29%	+$207K	0.22%	78
2021 Q3	$771K	Sell	10,314 -6,098	-37%	-$512K	0.3%	55
2021 Q2	$1.52M	Buy	16,412 +222	+1%	+$18.9K	0.62%	29
2021 Q1	$1.49M	Buy	16,190 +4,068	+34%	+$404K	0.66%	28
2020 Q4	$1.13M	Buy	12,122 +2,228	+23%	+$178K	0.61%	32
2020 Q3	$721K	Buy	9,894 +823	+9%	+$48.2K	0.46%	42
2020 Q2	$473K	Buy	9,071 +235	+3%	+$10.1K	0.38%	59
2020 Q1	$276K	Hold	8,836	–	–	0.3%	79
2019 Q4	$296K	Buy	+8,836	New	+$281K	0.28%	84

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $3.3B AUM 33.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Relyea Zuckerberg Hanson's ARKG Position: Q2 2024 in Review

Relyea Zuckerberg Hanson sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 10,256 shares — an estimated $295K sold.

Relyea Zuckerberg Hanson first reported a position in ARKG in Q4 2019 and held it in 16 quarters. The position peaked at $1.52M in Q2 2021. 263 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

Relyea Zuckerberg Hanson reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
Relyea Zuckerberg Hanson sold 10,256 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $295K.
Relyea Zuckerberg Hanson first reported a position in ARK Genomic Revolution ETF in Q4 2019 and held it in 16 quarters.
Relyea Zuckerberg Hanson's ARK Genomic Revolution ETF position peaked at $1.52M in Q2 2021.
263 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Relyea Zuckerberg Hanson's 13F filing for Q2 2024, filed 17 Jul 2024.